Tarsus Pharmaceuticals (TARS) PT Raised to $50 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Price: $68.20 -5.38%
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $50.00 (from $40.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- RingCentral (RNG) PT Raised to $105 at FBN Securities
- CACI International (CACI) PT Lowered to $823 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
